| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
104,690,000 |
| Market
Cap: |
110.01(B) |
| Last
Volume: |
507,716 |
Avg
Vol: |
759,306 |
| 52
Week Range: |
$692.45 - $1071.19 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
| |
NASDAQ COMPOSITE |
|
S&P SMALLCAP 600 |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 150 |
| Guru Rank Value : 6.9 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Regeneron Pharmaceuticals is a biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Co.'s products include: EYLEA (aflibercept) Injection, which is used for the treatment of neovascular age-related macular degeneration, diabetic macular edema, macular edema following retinal vein occlusion, myopic choroidal neovascularization, diabetic retinopathy, and neovascular glaucoma; REGEN-COV, which is used for the treatment of COVID-19; and Kevzara (sarilumab) Solution for Subcutaneous Injection, which is used for the treatment of rheumatoid arthritis.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
192,108 |
259,662 |
311,759 |
469,743 |
| Total Sell Value |
$188,697,290 |
$251,749,241 |
$294,950,701 |
$405,465,351 |
| Total People Sold |
7 |
14 |
16 |
18 |
| Total Sell Transactions |
18 |
45 |
67 |
128 |
| End Date |
2024-03-28 |
2023-12-26 |
2023-06-27 |
2022-06-27 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Stahl Neil |
EVP Research and Development |
• – – |
2020-05-11 |
4 |
S |
$567.50 |
$3,021,289 |
D/D |
(5,305) |
11,380 |
|
3% |
|
| Stahl Neil |
EVP Research and Development |
• – – |
2020-05-08 |
4 |
D |
$560.67 |
$4,034,021 |
D/D |
(7,195) |
16,685 |
|
- |
|
| Stahl Neil |
EVP Research and Development |
• – – |
2020-05-08 |
4 |
OE |
$52.03 |
$650,375 |
D/D |
12,500 |
23,880 |
|
- |
|
| Van Plew Daniel P |
EVP & General Mgr Industrial O |
• – – |
2020-05-07 |
4 |
S |
$556.92 |
$22,337,306 |
D/D |
(39,583) |
28,251 |
|
-4% |
|
| Zoghbi Huda Y |
Director |
– • – |
2020-05-07 |
4 |
S |
$565.64 |
$2,899,461 |
D/D |
(5,118) |
643 |
|
-4% |
|
| Zoghbi Huda Y |
Director |
– • – |
2020-05-07 |
4 |
OE |
$391.92 |
$2,005,847 |
D/D |
5,118 |
5,761 |
|
- |
|
| Brown Michael S |
Director |
– • – |
2020-05-07 |
4 |
S |
$562.00 |
$1,016,658 |
D/D |
(1,809) |
643 |
|
-4% |
|
| Ryan Arthur F |
Director |
– • – |
2020-05-06 |
4 |
GD |
$0.00 |
$0 |
D/D |
2,000 |
24,343 |
|
- |
|
| Van Plew Daniel P |
EVP & General Mgr Industrial O |
• – – |
2020-05-06 |
4 |
D |
$555.77 |
$25,563,197 |
D/D |
(45,996) |
67,834 |
|
- |
|
| Van Plew Daniel P |
EVP & General Mgr Industrial O |
• – – |
2020-05-06 |
4 |
OE |
$52.03 |
$4,452,675 |
D/D |
85,579 |
96,051 |
|
- |
|
| Tessier-Lavigne Marc |
Director |
– • – |
2020-05-06 |
4 |
S |
$562.65 |
$8,459,496 |
D/D |
(15,000) |
1,830 |
|
-5% |
|
| Tessier-Lavigne Marc |
Director |
– • – |
2020-05-06 |
4 |
OE |
$177.82 |
$2,667,300 |
D/D |
15,000 |
16,830 |
|
- |
|
| Brown Michael S |
Director |
– • – |
2020-05-06 |
4 |
D |
$555.77 |
$2,034,674 |
D/D |
(3,661) |
2,452 |
|
- |
|
| Brown Michael S |
Director |
– • – |
2020-05-06 |
4 |
OE |
$273.67 |
$2,034,739 |
D/D |
5,470 |
2,575 |
|
- |
|
| Ryan Arthur F |
Director |
– • – |
2020-05-06 |
4 |
S |
$541.66 |
$27,612,509 |
D/D |
(50,124) |
28,843 |
|
-5% |
|
| Ryan Arthur F |
Director |
– • – |
2020-05-06 |
4 |
OE |
$177.82 |
$18,729,670 |
D/D |
50,124 |
78,967 |
|
- |
|
| Goldstein Joseph L |
Director |
– • – |
2020-05-06 |
4 |
S |
$560.00 |
$1,120,000 |
D/D |
(2,000) |
7,643 |
|
-5% |
|
| Ryan Arthur F |
Director |
– • – |
2020-05-01 |
4 |
AS |
$517.41 |
$52,037 |
D/D |
(100) |
28,843 |
|
4% |
|
| Larosa Joseph J |
EVP General Counsel and Secret |
• – – |
2020-04-20 |
4 |
AS |
$561.57 |
$1,991,611 |
D/D |
(3,522) |
16,216 |
|
6% |
|
| Landry Robert E |
EVP Finance CFO |
• – – |
2020-04-20 |
4 |
AS |
$562.71 |
$1,842,539 |
D/D |
(3,250) |
24,373 |
|
6% |
|
| Larosa Joseph J |
EVP General Counsel and Secret |
• – – |
2020-04-20 |
4 |
AS |
$567.30 |
$1,013,985 |
D/D |
(1,778) |
14,438 |
|
6% |
|
| Larosa Joseph J |
EVP General Counsel and Secret |
• – – |
2020-04-17 |
4 |
D |
$555.82 |
$3,513,894 |
D/D |
(6,322) |
19,738 |
|
- |
|
| Larosa Joseph J |
EVP General Counsel and Secret |
• – – |
2020-04-17 |
4 |
OE |
$59.20 |
$688,022 |
D/D |
11,622 |
22,458 |
|
- |
|
| Larosa Joseph J |
EVP General Counsel and Secret |
• – – |
2020-04-17 |
4 |
AS |
$541.94 |
$1,263,586 |
D/D |
(2,267) |
14,438 |
|
8% |
|
| Landry Robert E |
EVP Finance CFO |
• – – |
2020-04-17 |
4 |
D |
$555.82 |
$5,141,335 |
D/D |
(9,250) |
27,623 |
|
- |
|
2430 Records found
|
|
Page 31 of 98 |
|
|
18.30 (1.71%) 
